Analysis for Bristol Myers Squibb
Analysis summary
Bristol Myers Squibb (BMY) currently has a total score of 42 points, placing it in the neutral range. The score is made up of Performance (20), Stability (55) and Trend (77). The profile is clearly uneven: Trend stands out while Performance lags.
Performance scores 20 points (weak). Least weak metric: 1Y return at 7.2 %. Main drag: 10Y return at -1.1 %. This points to a sharper upswing more recently.
Stability scores 55 points (neutral). Key strength: Sortino ratio (90d) at 5.04. Weaker metric: CAGR/drawdown ratio at -0.00. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.
Trend scores 77 points (strong). Key strength: trend strength at 0.96. Main drag: 12M momentum at 1.2 %.
Overall, the picture is mixed: Trend does the heavy lifting while Performance holds the score back. On a metric level, trend strength stands out, while 10Y return lags.
(Historical evaluation, not investment advice.)
Metrics
Stability
FAQ
- What investor type does Bristol Myers Squibb fit best in FoxScore?
- Bristol Myers Squibb fits a trend/momentum-oriented investor type in FoxScore: trend is clearly the strongest sub-score. This can be useful if you follow trends — but pay close attention to stability (drawdowns/volatility) because trend signals can flip quickly.
- How meaningful is the available history for Bristol Myers Squibb?
- Bristol Myers Squibb currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.
- What is FoxScore good for — and what is it not for?
- FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.